0001179110-16-030648.txt : 20161011
0001179110-16-030648.hdr.sgml : 20161011
20161011175823
ACCESSION NUMBER: 0001179110-16-030648
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20161006
FILED AS OF DATE: 20161011
DATE AS OF CHANGE: 20161011
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ACCELERON PHARMA INC
CENTRAL INDEX KEY: 0001280600
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 128 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-649-9200
MAIL ADDRESS:
STREET 1: 128 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kumar Ravindra
CENTRAL INDEX KEY: 0001586835
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36065
FILM NUMBER: 161932047
MAIL ADDRESS:
STREET 1: 128 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
edgar.xml
FORM 4 -
X0306
4
2016-10-06
0
0001280600
ACCELERON PHARMA INC
XLRN
0001586835
Kumar Ravindra
128 SIDNEY STREET
CAMBRIDGE
MA
02139
0
1
0
0
SVP & Chief Scientific Officer
Common Stock
2016-10-06
4
M
0
7124
5.28
A
91875
D
Common Stock
2016-10-06
4
S
0
14448
34.31
D
77427
D
Common Stock
2016-10-06
4
S
0
1561
34.98
D
75866
D
Common Stock
2016-10-07
4
M
0
954
3.88
A
76820
D
Common Stock
2016-10-07
4
M
0
10984
5.28
A
87804
D
Common Stock
2016-10-07
4
M
0
1115
5.28
A
88919
D
Common Stock
2016-10-07
4
M
0
2381
7.12
A
91300
D
Common Stock
2016-10-07
4
M
0
4210
24.11
A
95510
D
Common Stock
2016-10-07
4
S
0
19616
33.37
D
75894
D
Common Stock
2016-10-07
4
S
0
28
34
D
75866
D
Common Stock
2016-10-10
4
M
0
4182
7.12
A
80048
D
Common Stock
2016-10-10
4
M
0
8101
24.11
A
88149
D
Common Stock
2016-10-10
4
M
0
4550
27.97
A
92699
D
Common Stock
2016-10-10
4
S
0
16833
34.14
D
75866
D
Option to Purchase Common Stock
5.28
2016-10-06
4
M
0
7124
0
D
2022-06-07
Common Stock
7124
17876
D
Option to Purchase Common Stock
3.88
2016-10-07
4
M
0
954
0
D
2020-12-02
Common Stock
954
4561
D
Option to Purchase Common Stock
5.28
2016-10-07
4
M
0
10984
0
D
2021-12-16
Common Stock
10984
0
D
Option to Purchase Common Stock
5.28
2016-10-07
4
M
0
1115
0
D
2022-06-07
Common Stock
1115
16761
D
Option to Purchase Common Stock
7.12
2016-10-07
4
M
0
2381
0
D
2022-12-12
Common Stock
2381
5119
D
Option to Purchase Common Stock
24.11
2016-10-07
4
M
0
4210
0
D
2023-12-05
Common Stock
4210
24790
D
Option to Purchase Common Stock
7.12
2016-10-10
4
M
0
4182
0
D
2022-12-12
Common Stock
4182
937
D
Option to Purchase Common Stock
24.11
2016-10-10
4
M
0
8101
0
D
2023-12-05
Common Stock
8101
16689
D
Option to Purchase Common Stock
27.97
2016-10-10
4
M
0
4550
0
D
2026-03-03
Common Stock
4550
31850
D
The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.84 to $34.80 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.82 to $35.25 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.89 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.00 to $34.42 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) to this Form 4.
The options of registrant's common stock vest in equal quarterly installments over the first four years after the grant.
The options of registrant's common stock vest in equal quarterly installments over the four years after January 1, 2016.
/s/ John D. Quisel, as attorney-in-fact for Ravindra Kumar
2016-10-11